KR102847736B1 - 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 - Google Patents

변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체

Info

Publication number
KR102847736B1
KR102847736B1 KR1020247019564A KR20247019564A KR102847736B1 KR 102847736 B1 KR102847736 B1 KR 102847736B1 KR 1020247019564 A KR1020247019564 A KR 1020247019564A KR 20247019564 A KR20247019564 A KR 20247019564A KR 102847736 B1 KR102847736 B1 KR 102847736B1
Authority
KR
South Korea
Prior art keywords
ser
val
leu
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247019564A
Other languages
English (en)
Korean (ko)
Other versions
KR20240095463A (ko
Inventor
아론 얌니우크
마리 스트루더스
수잔 제이. 슈샤드
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20240095463A publication Critical patent/KR20240095463A/ko
Application granted granted Critical
Publication of KR102847736B1 publication Critical patent/KR102847736B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247019564A 2017-05-25 2018-05-24 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 Active KR102847736B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762511245P 2017-05-25 2017-05-25
US62/511,245 2017-05-25
KR1020197037759A KR20200012907A (ko) 2017-05-25 2018-05-24 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체
PCT/US2018/034330 WO2018217988A1 (en) 2017-05-25 2018-05-24 MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037759A Division KR20200012907A (ko) 2017-05-25 2018-05-24 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체

Publications (2)

Publication Number Publication Date
KR20240095463A KR20240095463A (ko) 2024-06-25
KR102847736B1 true KR102847736B1 (ko) 2025-08-18

Family

ID=62599725

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247019564A Active KR102847736B1 (ko) 2017-05-25 2018-05-24 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체
KR1020197037759A Ceased KR20200012907A (ko) 2017-05-25 2018-05-24 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197037759A Ceased KR20200012907A (ko) 2017-05-25 2018-05-24 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체

Country Status (6)

Country Link
US (2) US20200148779A1 (enExample)
EP (1) EP3630832A1 (enExample)
JP (2) JP2020521458A (enExample)
KR (2) KR102847736B1 (enExample)
CN (1) CN110637035A (enExample)
WO (1) WO2018217988A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP7762645B2 (ja) * 2019-08-22 2025-10-30 シダラ セラピューティクス インコーポレーテッド バリアントｆｃドメイン及びその使用
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US20230140384A1 (en) * 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
CN115443147A (zh) * 2020-04-23 2022-12-06 伊莱利利公司 抗体的皮下吸收和生物利用度
CN115867580A (zh) 2020-05-18 2023-03-28 百时美施贵宝公司 具有改进的药代动力学特性的抗体变体
CN112552389B (zh) * 2020-08-07 2023-06-06 中爱瑞祥(杭州)生物科技有限公司 一种活性肽融合蛋白及其制备方法
BR112023008317A2 (pt) * 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209445A1 (en) * 2004-03-26 2013-08-15 Xencor, Inc. Optimized Fc Variants
JP2014513953A (ja) * 2011-04-21 2014-06-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｄ４０を拮抗する抗体ポリペプチド

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP3342782B1 (en) * 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
AU2006304387A1 (en) * 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
US20170233485A1 (en) * 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
ES2826566T3 (es) * 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja) * 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
AU2016271111B2 (en) * 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
PE20181367A1 (es) * 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
US11220550B2 (en) * 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209445A1 (en) * 2004-03-26 2013-08-15 Xencor, Inc. Optimized Fc Variants
JP2014513953A (ja) * 2011-04-21 2014-06-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｄ４０を拮抗する抗体ポリペプチド

Also Published As

Publication number Publication date
KR20240095463A (ko) 2024-06-25
KR20200012907A (ko) 2020-02-05
JP2023113636A (ja) 2023-08-16
US20260042858A1 (en) 2026-02-12
WO2018217988A1 (en) 2018-11-29
WO2018217988A9 (en) 2019-05-02
JP2020521458A (ja) 2020-07-27
US20200148779A1 (en) 2020-05-14
CN110637035A (zh) 2019-12-31
EP3630832A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
US20260042858A1 (en) Modified IgG1 Fc Domains and Anti-CD40 Domain Antibody Fusions Therewith
US11613585B2 (en) Nucleic acids encoding antagonistic CD40 monoclonal antibodies
TWI800694B (zh) 拮抗性cd40單株抗體及其用途
EP3464367B1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
EP3988577A1 (en) Anti-cd137 antibodies
CN113195523A (zh) IL-12异源二聚体Fc融合蛋白
CN113423734A (zh) 靶向PD-1的IL-15/IL-15RαFC融合蛋白及其在联合疗法中的应用
CN115916233A (zh) 靶向IL-12异源二聚体Fc融合蛋白
US20170304437A1 (en) Bispecific molecules capable of specifically binding to both ctla-4 and cd40
JP2023521582A (ja) 改変Ｃ末端ｃｒｏｓｓｆａｂ断片を含む二重特異性抗体
US12435131B2 (en) Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
EP3374399A1 (en) Composition and methods for anti-tnfr2 antibodies
EP4582804A1 (en) Method for screening and preparing immunomodulator
CN114616247A (zh) Ox40/pd-l1双特异性抗体
HK40073076A (en) Anti-cd137 antibodies
KR20240053675A (ko) sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법
HK40058870A (zh) Il-12异源二聚体fc融合蛋白
EA048273B1 (ru) Антагонистические моноклональные антитела к cd40 и их применения
HK40050240A (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
EA051364B1 (ru) Улучшенные антигенсвязывающие рецепторы

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)